CHICAGO & BARCELONA, Spain–(BUSINESS WIRE)–At the European Association of Nuclear Medicine (EANM) Annual Meeting, GE Healthcare proudly presents Omni LegendI, the first system in its all-new, all-digital PET/CT platform. This state-of-the-art system features an all-new class of digital BGO (dBGO) detector material with a small crystal size that delivers more than twice the sensitivity of previous digital scannersiiallowing faster total analysis timesiii and impressive detectability of small lesionsiv. It is designed to improve operational efficiency, improve patient experience and increase diagnostic power, ideally helping to enable better patient outcomes.
In addition, system theranosticsv capabilities and ability to image short-lived tracers, as well as dynamic protocolsvihelp clinicians have more clinical information about more types of procedures in oncology, cardiology and neurology than ever before.
“Sensitivity and image quality are paramount in PET/CT,” says John Kennedy, Ph.D., Chief Physicist, Department of Nuclear Medicine, Rambam Health Care Campus, and Senior Lecturer at the Technion – Israel Institute of Technologyviii. “Omni Legend ticks both boxes: it meets all of our image quality criteria for oncology and offers impressive sensitivity to high-count image tracers for cardiac and neurological imaging, allowing better illumination diagnostics and patient monitoring. Additionally, we were able to increase patient throughput by more than a third due to the system’s fast total scan times – even completing 35 patient scans in 9.5 hours – and reduce dose by 40% compared to previous equipment that was installed. This not only improves patient access and experience, but also allows us to increase overall hospital efficiency.viii.”
As the pace of change in healthcare continues to accelerate, health plan leaders cite managing costs and improving operational efficiencies as the top two challenges they face todayix. This is consistent with feedback from global molecular imaging departments, which note operational efficiency as a major impediment to growth in PET/CT procedure volumes.X.
Omni Legend is GE Healthcare’s answer to these growing challenges, helping healthcare systems overcome current obstacles with a collection of intuitive artificial intelligence (AI)-enhanced workflow solutions, including its new Precision DLI solution for deep learning PET/CT image processing as well as its AI-based automatic positioning camera.
“Having access to high-quality images to determine patient care is fundamental to delivering quality healthcare,” adds Professor Zohar Keidar, Director of Nuclear Medicine and PET/CT Department at Rambam and Associate Professor of clinic at the Technion Medical School.viii. “With this in mind, a department like ours – which has a very heavy workload – needs a system that allows flexibility for emergencies, in addition to our already busy schedules. Omni Legend offers this flexibility. In a few weeks/months, we were able to increase our number of scans by 150%, from 30 to 45 patient scans per day. We had a long waiting list; but today, if something is urgent, we can quickly scan a patient while keeping our other appointments scheduledviii. And the system’s clinical protocols provide us with additional flexibility, allowing us to classify patients on any scanner, regardless of the system the patients were previously scanned on, giving us new opportunities in managing fleet.
More than a new treatment technique, Precision DLI is designed using Deep Learning with a sophisticated deep neural network trained on thousands of images created with different reconstruction methods. It was designed to provide the image quality performance benefits most associated with hardware time-of-flight, such as better contrast-to-noise ratio, contrast recovery, and quantitative accuracy.
Omni Legend’s capabilities are further enhanced by the inclusion of Q.Clear (BSREM), GE Healthcare’s pioneering PET image reconstruction technology, and MotionFree, GE Healthcare’s proven device-free respiratory motion correction technology. society. Q.Clear helps ensure reliable quantitation, while MotionFree works seamlessly in the background to correct respiratory motion artifacts for all patient types.
Additionally, the new system’s operational efficiency solutions help improve the PET/CT imaging experience for both technologist and patient with convenient features that provide:
A fast data quality assurance process that saves time with simplified calibration;
Simplified protocol selection on the gantry touch screen and a new user interface to enable an easy PET/CT process from start to finish; and
Improved patient positioning capabilities with AI-powered automatic positioning that automatically centers the patient for a completely hands-free positioning experience.
This simplified patient setup allows technologists to focus on making patients feel more comfortable. Omni Legend also features LED mood lighting to encourage a soothing ambience as well as a graphic pattern the patient can view in the system to help both relieve stress and reduce movement for nervous patients.
“We built our scalable Omni platform from the ground up to meet the needs of our customers and their patients today and in the future,” said Jean-Luc Procaccini, President and CEO, Molecular Imaging & Computed Tomography, GE Healthcare. “With the patient in mind, we’ve built on our longstanding technology leadership and strong clinical collaborations to enhance the scanning experience with entirely new components designed to help improve clinical outcomes. The result is a fully digital detector, a state-of-the-art deep learning solution, and workflow enhancements to enable more personalized care. »
Omni Legend was designed with theranostics in mind, allowing clinicians to achieve new levels of sensitivity and detectability for incredibly clear images. Already the system has the highest sensitivity per cm on the marketxi and Gallium 68 images for diagnosis, staging or restaging.
Future-ready features include a multi-directional, scalable platform that can potentially expand into each of the critical dimensions of PET/CT imaging, including axial field of view, digital sensing technology, software , CT capabilities and new tracer imaging .
For more information on GE Healthcare’s new Omni PET/CT platform and Omni Legend system, please visit gehealthcare.com.
About GE Healthcare:
GE Healthcare is the $17.7 billion healthcare business of GE (NYSE: GE). As a global leader in medical technology, pharmaceutical diagnostics and digital solutions innovation, GE Healthcare empowers clinicians to make faster, more informed decisions through smart devices, data analytics, apps and services, supported by its Edison intelligence platform. With more than 100 years of experience in the healthcare industry and approximately 48,000 employees worldwide, the company operates at the center of an ecosystem driving precision health, digitizing healthcare, helping to drive the productivity and improve outcomes for patients, providers, health systems and researchers around the world.
I Omni Legend and Precision DL are CE marked. Omni Legend is 510(k) cleared by the US FDA. Precision DL is pending 510(k) with the US FDA. Not available for sale in the United States.
ii Omni Legend 32cm has up to 2.2 increase in system sensitivity compared to Discovery MI 25cm. Measurement follows NEMA NU 2-2018.
iii Up to 53% reduction in PET scan time on the Omni Legend 32cm compared to the Discovery MI 25cm, as demonstrated in phantom testing.
iv Omni Legend 32cm increases the detectability of small lesions by an average of 16% and up to 20%, compared to the Discovery MI 25cm with adapted scan duration/shot dose, as demonstrated in phantom testing using a model observer with lesions of 4 mm; average of the different reconstruction methods.
v Omni Legend is able to image the diagnostic part of Theranostics
vi Short-lived tracers such as Rubidium-82 used in PET cardiology scans. For dynamic protocols such as Whole Body Dynamic Acquisition, the Dynamic IQ processing app is required. Dynamic IQ is CE marked. It is pending 510(k) with the US FDA. Not cleared or approved by the US FDA. Not for sale in the United States.
viii Not a Consultant for GEHC: The statements of GE customers described herein are based on their own opinions and on results that have been obtained in the customer’s unique setting. Since there is no “typical” hospital and there are many variables, such as hospital size, case mix, etc., there is no guarantee that other customers will get the same results.
viii GE Healthcare does not warrant or guarantee these results. The ability to achieve such results depends on factors unique to each client.
ix “The HealthEdge Survey Highlights Growth Opportunities and Challenges for Health Plan Leaders.” HealthEdge. April 9, 2022. https://www.healthedge.com/about-us/news-events/press-releases/healthedge-survey-highlights-growth-opportunities-and-challenges-for-health-plan-leaders
X Data on file.
xi Data on file.